Where did all the acne go?

In recent years, a noticeable shift has taken place in the prevalence of severe acne among teenagers and young adults in New Zealand. Once a common and often distressing condition, cystic acne, marked by deep, painful pimples and potential scarring, is becoming less frequent than in previous decades. This change coincides with the widespread availability of isotretinoin, a powerful medication previously reserved for severe cases and accessible only through specialist dermatologists. The transformation began in 2009 with a key policy adjustment that allowed general practitioners (GPs) to prescribe isotretinoin directly, bypassing the need for referrals to dermatologists. Prior to this change, obtaining the drug required lengthy waits and access to a limited number of specialists. New Zealand's shortage of dermatologists, approximately 80 nationwide compared to Australia's three times higher number, meant that many patients faced delays or high costs associated with specialist consultations. Dr. AJ Seine, a specialist dermatologist and spokesperson for the New Zealand Dermatological Society, noted that the policy change significantly improved access to effective treatments. Since 2009, the annual prescription rate for isotretinoin has surged by 87 percent, rising from 26,897 in 2008 to 50,613 in 2023. This increase reflects both greater awareness of the drug’s benefits and easier access through primary care providers. For individuals like Sophie Dunn, the impact of this policy change has been profound. She developed acne in her mid-20s, a condition that persisted for several years despite various treatments. As her wedding approached, she sought a definitive solution. Her GP recommended isotretinoin, a decision that surprised her given the severity of her condition. “I thought my skin would have to be much worse to warrant it,” she recalled. The ease of accessing the medication played a crucial role in her decision, as seeing a dermatologist was both costly and inconvenient for many. The broader implications of this shift extend beyond individual experiences. Acne, once considered a near-universal experience during adolescence, continues to affect 85 percent of people in New Zealand at some stage in life. However, the proportion of individuals developing severe forms of the condition appears to be declining. This trend aligns with the increased use of isotretinoin, which has proven highly effective in treating even the most resistant cases. The change in prescribing practices has also influenced public perception and behavior surrounding acne. Products such as pimple patches, which blend functionality with aesthetic appeal, have gained popularity among younger generations. These items reflect a cultural shift toward embracing skincare solutions that are both practical and visually appealing, rather than relying solely on concealment methods like heavy makeup. Despite these advancements, challenges remain. While isotretinoin is widely available, it requires careful monitoring due to its potential side effects. Patients must undergo regular check-ups and follow specific guidelines to ensure safe usage. Additionally, disparities in access persist, particularly in rural areas where healthcare resources are more limited. As the landscape of acne treatment evolves, ongoing research into alternative therapies and preventive measures continues. Dermatologists emphasize the importance of early intervention and personalized treatment plans to address the diverse needs of patients. The success of policies like the 2009 change highlights the value of adapting healthcare strategies to meet the demands of changing medical landscapes and societal expectations.